این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Nuclear Medicine، جلد ۳۰، شماره ۲، صفحات ۱۱۵-۱۲۱
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer
چکیده انگلیسی مقاله Introduction: Targeted radionuclide therapy with [177Lu]Lu-prostate-specific membrane antigen (PSMA) has shown promising results for the treatment of castration-resistant prostate cancer (mCRPC). Nevertheless, a proportion of patients do not respond to this therapy. Here, we aimed to evaluate the prognostic significance of the pretreatment pathologic and laboratory factors for the prediction of biochemical response to the first cycle of [177Lu]Lu-PSMA therapy.Methods: In this retrospective study, mCRPC patients, referred for [177Lu]Lu-PSMA therapy, were included. We retrieved the data of patients, undergone [177Lu]Lu-PSMA, from March 2019 to March 2021. Multiple baseline pathologic and laboratory parameters were extracted and correlated with the response to the first cycle. The prostate-specific antigen (PSA) level was evaluated six weeks after [177Lu]Lu-PSMA therapy for the biochemical response.Results: Forty-three patients with a mean age of 69.8±10.2 were included. Bone and visceral metastases were present in 81.4% and 14.0% of the patients, respectively. Except for two, all patients had received hormone- and chemotherapy. The mean PSA level was 189.9±259.0 at baseline. Following one cycle of [177Lu]Lu-PSMA, “≥ 10% PSA response” and “≥ 50% PSA response” were seen in 81.4% and 44.2% of the patients, respectively. Patients with higher baseline PSA more frequently had ≥ 10% PSA response (p= 0.004). Also, the reduction in the PSA level correlated with baseline PSA (p=0.013, r=0.375).Conclusion: [177Lu]Lu-PSMA therapy results in the biochemical response in a considerable number of patients after one cycle. In nearly half of patients, PSA declines more than 50%. Higher baseline PSA is correlated with the level of PSA response.
کلیدواژه‌های انگلیسی مقاله castration-resistant prostate cancer, mCRPC, Lu-PSMA, Radioligand therapy, PSA response
نویسندگان مقاله Ahmed Al-Timimi |
Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Reyhaneh Manafi-Farid |
Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Babak Fallahi |
Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Davood Beiki |
Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Emran Askari |
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Alireza Rezaei |
Khatam PET/CT Center, Khatam Al-Anbia Hospital, Tehran, Iran

Zohreh Adinehpour |
Khatam PET/CT Center, Khatam Al-Anbia Hospital, Tehran, Iran

Mohammad Eftekhari |
Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

نشانی اینترنتی http://irjnm.tums.ac.ir/article_40019_a111d7bea99df6a11bc8f4c0240641a0.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات